Zobrazeno 1 - 10
of 1 966
pro vyhledávání: '"S Vermeire"'
Publikováno v:
Scandinavian Journal of Gastroenterology. :1-9
Publikováno v:
Acta Gastro Enterologica Belgica. 86:98-101
Crohn’s disease (CD) is a chronic inflammatory bowel disease often presenting with extraintestinal manifestations. However, pulmonary involvement in CD is quite rare. We here report a case of CD with pulmonary manifestation as the first presenting
Autor:
G. Sarrabayrouse, A. Elias, F. Yáñez, L. Mayorga, E. Varela, C. Bartoli, F. Casellas, N. Borruel, C. Herrera de Guise, K. Machiels, S. Vermeire, C. Manichanh
Publikováno v:
mSystems, Vol 6, Iss 2 (2021)
ABSTRACT Microbiome sequence data have been used to characterize Crohn's disease (CD) and ulcerative colitis (UC). Based on these data, we have previously identified microbiomarkers at the genus level to predict CD and CD relapse. However, microbial
Externí odkaz:
https://doaj.org/article/2974d625b5e24216b1cba5690fe2589e
Autor:
B Sands, L Peyrin-Biroulet, S Danese, D T Rubin, S Vermeire, O Laurent, A Luo, D Nguyen, J D Lu, A Wiechowska-Kozlowska, J Leszczyszyn, R Kempinski, J Kierkus, C Ma, T Ritter, B G Feagan, S Targan
Publikováno v:
Journal of Crohn's and Colitis. 17:i56-i59
Background Tumor necrosis factor-like cytokine 1A (TL1A) is an upstream regulator of pro-inflammatory cytokines and fibrosis signals. PRA023 is an anti-TL1A monoclonal antibody in development for multiple inflammatory/fibrotic diseases using a precis
Autor:
V Jairath, G Zou, G Radulescu, J Sigler, S C Mcfarlane, S Adsul, M Freire, L Peyrin-Biroulet, J F Colombel, G W Moran, S Sebastian, S Travis, S Vermeire, W J Sandborn, G R D’Haens, B G Feagan
Publikováno v:
Journal of Crohn's and Colitis. 17:i826-i829
Background Symptoms, endoscopy, histology, and biomarkers are used to evaluate disease activity and response to therapy in ulcerative colitis (UC). Histologic disease activity may persist in ~25% of patients with normal-appearing endoscopic mucosa, a
Autor:
B Siegmund, H K Komori, M T Abreu, S Vermeire, I Dotan, M Goetsch, C Crosby, R Ryan, J Woolcott, S Danese
Publikováno v:
Journal of Crohn's and Colitis. 17:i701-i704
Background Etrasimod is an investigational, once-daily, oral, selective sphingosine 1-phosphate receptor 1,4,5 (S1P1,4,5) modulator in development for the treatment of moderately to severely active ulcerative colitis (UC). Etrasimod reversibly seques
Autor:
S Vermeire, S Danese, B L Cohen, F Magro, Y Chen, C Ha, E Dubcenco, A P Lacerda, E Marced, J Oomen, A Garrison, L Peyrin-Biroulet
Publikováno v:
Journal of Crohn's and Colitis. 17:i510-i513
Background Improvement in clinical outcomes and normalisation of objective markers of inflammation, high-sensitivity C-reactive protein (hs-CRP) and faecal calprotectin (FCP), are considered treatment targets per STRIDE-II guidelines.1 We evaluated t
Publikováno v:
Journal of Crohn's and Colitis. 17:i501-i505
Background Subcutaneous (SC) formulations of infliximab (IFX) and vedolizumab (VDZ) were recently approved for maintenance treatment of patients with inflammatory bowel disease. However, further investigation is required to identify the patients most
Autor:
D T Rubin, J Panés, J Torres, T Kobayashi, C Su, N Lawendy, I Modesto, M Segovia, S Gardiner, W Wang, S Vermeire
Publikováno v:
Journal of Crohn's and Colitis. 17:i914-i916
Background Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. The long-term, Phase 3b/4 RIVETING study (NCT03281304) assessed the efficacy and safety of tofacitinib dose reduction from tofacitinib 10
Autor:
C O'Neill, S Haenen, W Coudyzer, G Bislenghi, A D'Hoore, B Verstockt, M Ferrante, S Vermeire, J Sabino
Publikováno v:
Journal of Crohn's and Colitis. 17:i319-i321
Background Sarcopenia (loss of skeletal muscle mass and/or strength) is a predictor of postoperative morbidity in various surgical populations. We evaluated the impact of sarcopenia in postoperative outcomes after intestinal surgery in patients with